Psoriatic Arthritis

  • Dafna D. Gladman


Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis (1). Psoriasis is an inflammatory skin condition that presents with a red scaly rash often on the extensor surfaces but may also affect the scalp and flexural areas as well as palms and soles (2). It commonly affects the nails with either pits or onycholysis. Up to one third of patients with psoriasis may develop an inflammatory arthritis presenting with pain and stiffness in the affected joints. Both psoriasis and PsA affect men and women equally. PsA was distinguished from rheumatoid arthritis (RA), the prototype inflammatory arthritis, in the middle of the past century with the discovery of rheumatoid factor (RF). Whereas 85% of patients with RA are RF positive, patients with psoriatic arthritis are usually seronegative for RF. Earlier studies using the latex fixation test suggested that up to 15% of patients with PsA were seropositive (3), but more recent studies using either nephelometry or enzyme-linked immunosorbent assay (ELISA) tests reveal a prevalence of only 4% to 5% (4).


Rheumatoid Arthritis Human Leukocyte Antigen Major Histocompatibility Complex Class Rheumatoid Factor Psoriatic Arthritis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Wright V, Moll JMH. Psoriatic arthritis. In: Seronegative polyarthritis. Amsterdam: North Holland Publishing; 1976:169–223.Google Scholar
  2. 2.
    Langley RGB, Krueger GG, Griffiths CEM. Psoriasis: epidemiology, clinical features and quality of life. Ann Rheum Dis 2005;64:18–23.CrossRefGoogle Scholar
  3. 3.
    Gladman DD, Shuckett R, Russell ML, et al. Psoriatic arthritis (PSA)—an analysis of 220 patients. Q J Med 1987;62:127–141.PubMedGoogle Scholar
  4. 4.
    Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H; CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665–2673.PubMedCrossRefGoogle Scholar
  5. 5.
    Gladman DD. Epidemiology. Psoriatic arthritis. In: Gordon GB, Ruderman E, eds. Psoriasis and psoriatic arthritis: an integrated approach. Heidelberg: Springer-Verlag; 2005:57–65.CrossRefGoogle Scholar
  6. 6.
    Madland TM, Apalset EM, Johannessen AE, Rossebo B, Brun JG. Prevalence, disease manifestations, and treatment of psoriatic arthritis in Western Norway. J Rheumatol 2005;32:1918–1922.PubMedGoogle Scholar
  7. 7.
    Shbeeb M, Uramoto KM, Gibson LE, et al. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982–1991. J Rheumatol 2000;27:1247–1250.PubMedGoogle Scholar
  8. 8.
    Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 2003;4:441–447.PubMedCrossRefGoogle Scholar
  9. 9.
    Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the United States population. J Am Acad Dermatol 2005;53:573–577.PubMedCrossRefGoogle Scholar
  10. 10.
    Scarpa R, Oriente P, Pulino A, et al. Psoriatic arthritis in psoriatic patients. Br J Rheumatol 1984;23:246–250.PubMedCrossRefGoogle Scholar
  11. 11.
    Fournie B, Crognier L, Arnaud C, et al. Proposed classification criteria of psoriatic arthritis. A preliminary study in 260 patients. Rev Rheum Engl Ed 1999;66:446–456.Google Scholar
  12. 12.
    Taylor WJ, Marchesoni A, Arreghini M, et al. A comparison of the performance characteristics of classification criteria for the diagnosis of psoriatic arthritis. Semin Arthritis Rheum 2004;34:575–584.PubMedCrossRefGoogle Scholar
  13. 13.
    Kammer GM, Soter NA, Gibson DJ, et al. Psoriatic arthritis: clinical, immunologic and HLA study of 100 patients. Semin Arthritis Rheum 1979;9:575–97.CrossRefGoogle Scholar
  14. 14.
    Helliwell P, Marchesoni A, Peters M, et al. A reevaluation of the osteoarticular manifestations of psoriasis. Br J Rheumatol 1991;30:339–345.PubMedCrossRefGoogle Scholar
  15. 15.
    Torre Alonso JC, Perez AR, Castrillo JMA, et al. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol 1991;30:245–250.PubMedCrossRefGoogle Scholar
  16. 16.
    Veale D, Rogers S, Fitzgerald O. Classification of clinical subsets in psoriatic arthritis. Br J Rheumatol 1994;33:133–138.PubMedCrossRefGoogle Scholar
  17. 17.
    Jones SM, Armas JB, Cohen MG, et al. Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol 1994;33:834–839.PubMedCrossRefGoogle Scholar
  18. 18.
    Salvarani C, Macchioni PL, Zizzi F. Clinical subgroups and HLA antigens in Italian patients with psoriatic arthritis. Clin Exp Rheumatol 1989;7:391–396.PubMedGoogle Scholar
  19. 19.
    Scarpa R, Biondi OC, Oriente P. The classification of psoriatic arthritis: what will happen in the future? J Am Acad Dermatol 1997;36:78–83.PubMedCrossRefGoogle Scholar
  20. 20.
    Marsal S, Armadans-Gil L, Martinez M, Gallardo D, Ribera A, Lience E. Clinical, radiographic and HLA associations as markers for different patterns of psoriatic arthritis. Rheumatology (Oxford) 1999;38:332–337.CrossRefGoogle Scholar
  21. 21.
    Kane D, Stafford L, Bresnihan B, FitzGerald O. A classification study of clinical subsets in an inception cohort of early psoriatic peripheral arthritis—“DIP or not DIP revisited”. Rheumatology (Oxford) 2003;42:1469–1476.CrossRefGoogle Scholar
  22. 22.
    Khan M, Schentag C, Gladman D. Clinical and radiological changes during psoriatic arthritis disease progression: working toward classification criteria. J Rheumatol 2003;30:1022–1026.PubMedGoogle Scholar
  23. 23.
    McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford) 2003;42:778–783.CrossRefGoogle Scholar
  24. 24.
    Helliwell PS, Hetthen J, Sokoll K, et al. Joint symmetry in early and late rheumatoid and psoriatic arthritis: comparison with a mathematical model. Arthritis Rheum 2000;43:865–871.PubMedCrossRefGoogle Scholar
  25. 25.
    Buskila D, Langevitz P, Gladman DD, et al.Patients with rheumatoid arthritis are more tender than those with psoriatic arthritis. J Rheumatol 1992;19:1115–1119.PubMedGoogle Scholar
  26. 26.
    Jajic I. Blue coloured skin in psoriatic arthritis. Clin Exp Rheumatol 2001;19:478.PubMedGoogle Scholar
  27. 27.
    Lambert JB, Wright V. Psoriatic spondylitis: a clinical and radiological description of the spine in psoriatic arthritis. Q J Med 1977;46:411–425.PubMedGoogle Scholar
  28. 28.
    Hanly J, Russell ML, Gladman DD. Psoriatic spondyloarthropathy: a long term prospective study. Ann Rheum Dis 1988;47:386–393.PubMedCrossRefGoogle Scholar
  29. 29.
    Salvarani C, Macchioni P, Cromones T, et al. The cervical spine in patients with psoriatic arthritis: a clinical, radiological and immunogenetic study. Ann Rheum Dis 1992;51:73–77.PubMedCrossRefGoogle Scholar
  30. 30.
    Ballistone MJ, Manaster BJ, Reda DJ, et al. The prevlance of sacroiliitis in psoriatic arthritis: new perspectives from a large, multicenter cohort. Skeletal Radiol 1999;28:196–201.CrossRefGoogle Scholar
  31. 31.
    Gladman DD, Brubacher B, Buskila D, et al. Differences in the expression of spondyloarthropathy: a comparison between ankylosing spondylitis and psoriatic arthritis. Genetic and gender effects. Clin Invest Med 1993;16:1–7.PubMedGoogle Scholar
  32. 32.
    Kane D, Gearney T, Bresnihan B, Gibney R, Fitzgerald O. Ultrasonography in the diagnosis and management of psoriatic dactylitis. J Rheumatol 1999;25:1746–1751.Google Scholar
  33. 33.
    Olivieri I, Barozzi L, Favaro L, et al. Dactylitis in patients with seronegative spondyloarthropathy. Arthritis Rheum 1996;39:1524–1528.PubMedCrossRefGoogle Scholar
  34. 34.
    Brockbank J, Stein M, Schentag CT, et al. Characteristics of dactylitis in psoriatic arthritis (PsA). Ann Rheum Dis 2005;62:188–190.CrossRefGoogle Scholar
  35. 35.
    Helliwell PS, Firth J, Ibrahim GH, et al. Development of an assessment tool for dactylitis in patients with psoriatic arthritis. J Rheumatol 2005;32:1745–1750.PubMedGoogle Scholar
  36. 36.
    Cantini F, Salvarani C, Olivieri I, et al. Distal extremity swelling with pitting edema in psoriatic arthritis: a case-control study. Clin Exp Rheumatol 2001;19:291–296.PubMedGoogle Scholar
  37. 37.
    Salvarani C, Cantini F, Olivieri I, et al. Distal extremity swelling with pitting edema in psoriatic arthritis: evidence of 2 pathological mechanisms. J Rheumatol 1999;26:1831–1834.PubMedGoogle Scholar
  38. 38.
    Salvarani C, Cantini F, Olivieri I, et al. Isolated peripheral enthesitis and/or dactylitis: a subset of psoriatic arthritis. J Rheumatol 1997;24:1106–1110.PubMedGoogle Scholar
  39. 39.
    Cohen MR, Reda DJ, Clegg DO. Baseline relationships between psoriasis and psoriatic arthritis: analysis of 221 patients with active psoriatic arthritis. J Rheumatol 1999;26:1752–1756.PubMedGoogle Scholar
  40. 40.
    Elkayam O, Ophir J, Yaron M, Caspi D. Psoriatic arthritis: interrelationships between skin and joint manifestations related to onset, course and distribution. Clin Rheumatol 2000;19:301–305.PubMedCrossRefGoogle Scholar
  41. 41.
    Gladman DD, Anhorn KB, Schachter RK, et al. HLA antigens in psoriatic arthritis. J Rheumatol 1986;13:586–592.PubMedGoogle Scholar
  42. 42.
    Williamson L, Dockerty JL, Dalbeth N, et al. Gastrointestinal disease and psoriatic arthritis. J Rheumatol 2004;31:1469–1470.PubMedGoogle Scholar
  43. 43.
    Scarpa R, Manguso F, D’Arienzo A, et al. Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms. J Rheumatol 2000;27:1241–1246.PubMedGoogle Scholar
  44. 44.
    Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, et al. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 2004;34:585–592.PubMedCrossRefGoogle Scholar
  45. 45.
    Bruce IN, Schentag C, Gladman DD. Hyperuricemia in psoriatic arthritis (PsA) does not reflect the extent of skin involvement. J Clin Rheumatol 2000;6:6–9.PubMedCrossRefGoogle Scholar
  46. 46.
    Gladman DD. Clinical aspects of spondyloarthropathies. Am J Med Sci 1998;316:234–238.PubMedCrossRefGoogle Scholar
  47. 47.
    Coulton BL, Thomson K, Symmons DPM, et al. Outcome in patients hospitalised for psoriatic arthritis. Clin Rheumatol 1989;2:261–265.CrossRefGoogle Scholar
  48. 48.
    Kane D, Stafford L, Bresniham B, et al. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience Rheumatology 2003;42:1460–1468.PubMedCrossRefGoogle Scholar
  49. 49.
    Gladman DD, Stafford-Brady F, Chang CH, et al. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 1990;17:809–812.PubMedGoogle Scholar
  50. 50.
    Siannis F, Farewell VT, Cook RJ, et al. Clinical and radiological damage in psoriatic arthritis. Ann Rheum Dis 2006;65:478–481.PubMedCrossRefGoogle Scholar
  51. 51.
    Gladman DD, Farewell VT, Nadeau C. Clinical indicators of progression in psoriatic arthritis (PSA): multivariate relative risk model. J Rheumatol 1995;22:675–679.PubMedGoogle Scholar
  52. 52.
    Queiro-Silva R, Torre-Alonso JC, Tinture-Eguren T,et al. A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis. Ann Rheum Dis 2003;62:68–70.PubMedCrossRefGoogle Scholar
  53. 53.
    Gladman DD, Farewell VT. Progression in psoriatic arthritis: role of time varying clinical indicators. J Rheumatol 1999;26:2409–2213.Google Scholar
  54. 54.
    Gladman DD, Ng Tung Hing E, Schentag CT, et al. Remission in psoriatic arthritis. J Rheumatol 2001;28:1045–1048.PubMedGoogle Scholar
  55. 55.
    Blackmore M, Gladman DD, Husted J, et al. Measuring health status in psoriatic arthritis: the Health Assessment Questionnaire and its modification. J Rheumatol 1995;22:886–893.PubMedGoogle Scholar
  56. 56.
    Husted J, Gladman DD, Long JA, Farewell VT, Cook R. Validating the SF-36 health questionnaire in patients with psoriatic arthritis. J Rheumatol 1997;24:511–517.PubMedGoogle Scholar
  57. 57.
    Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol 2001;28:1842–1846.PubMedGoogle Scholar
  58. 58.
    Husted JA, Gladman DD, Farewell VT, et al. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Care Res 2001;45:151–158.CrossRefGoogle Scholar
  59. 59.
    Husted JA, Brian T, Farewell VT, et al. Description and prediction of physical functional disability in psoriatic arthritis (psa): a longitudinal analysis using a Markov model approach. Arthritis Rheum 2005;53:404–409.PubMedCrossRefGoogle Scholar
  60. 60.
    Wong K, Gladman DD, Husted J, et al. Mortality studies in psoriatic arthritis. Results from a single centre. I. Risk and Causes of Death. Arthritis Rheum 1997;40:1868–1872.PubMedCrossRefGoogle Scholar
  61. 61.
    Gladman DD, Farewell VT, Husted J, et al. Mortality studies in psoriatic arthritis. Results from a single centre. II. Prognostic indicators for mortality. Arthritis Rheum 1998;41:1103–1110.PubMedCrossRefGoogle Scholar
  62. 62.
    Ali Y, Tom B, Schentag C, et al. Did mortality rate improve in psoriatic arthritis (PsA) patients in the last decade? J Rheumatol 2006;33:386.Google Scholar
  63. 63.
    Chandran V, Schentag CT, Gladman D. A Reappraisal of the effectiveness of methotrexate (MTX) in psoriatic arthritis (PsA): a clinic experience. Arthritis Rheum 2005;52(Suppl 9):S638.Google Scholar
  64. 64.
    Leczinsky CG. The incidence of arthropathy in a ten-year series of psoriasis cases. Acta Derm Venereol 1948;28:483–487.PubMedGoogle Scholar
  65. 65.
    Vilanova X, Pinol J. Psoriasis arthropathica. Rheumatism 1951;7:197–208.PubMedGoogle Scholar
  66. 66.
    Little H, Harvie JN, Lester RS. Psoriatic arthritis in severe psoriasis. Can Med Assoc J 1975;112:317–319.PubMedGoogle Scholar
  67. 67.
    Leonard DG, O’Duffy JD, Rogers RS. Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis. Mayo Clin Proc 1978;53:511–518.PubMedGoogle Scholar
  68. 68.
    Green L, Meyers OL, Gordon W, Briggs B. Arthritis in psoriasis. Ann Rheum Dis 1981;40:366–369.PubMedCrossRefGoogle Scholar
  69. 69.
    Stern RS. The epidemiology of joint complaints in patients with psoriasis. J Rheumatol 1985;12:315–320.PubMedGoogle Scholar
  70. 70.
    Zanelli MD, Wilde JS. Joint complaints in psoriasis patients. Int J Dermatol 1992;31:488–491.CrossRefGoogle Scholar
  71. 71.
    Falk ES, Vandbakk Ø. Prevalence of psoriasis in a Norwegian Lapp population. Acta Derm Venereol (Stockh) 1993;182:6–9.Google Scholar
  72. 72.
    Barišic-Druško V, Dobric I, Pašic A, et al. Frequency of psoriatic arthritis in general population and among psoriatics in department of dermatology. Acta Derm Venerol (Stockh) 1994;74(Suppl 186):107–108.Google Scholar
  73. 73.
    Salvarani C, Socco GL, Macchioni P, et al. Prevalence of psoriatic arthritis in Italian patients with psoriasis. J Rheumatol 1995;22:1499–1503.PubMedGoogle Scholar
  74. 74.
    Brockbank JE, Schentag C, Rosen C, et al. Psoriatic arthritis (PsA) is common among patients with psoriasis and family medical clinic attendees. Arthritis Rheum 2001;44(Suppl 9):S94.Google Scholar
  75. 75.
    Alenius GM, Stenberg B, Stenlund H, et al. Inflammatory joint manifestations are prevalent in psoriasis: prevalence study of joint and axial involvement in psoriatic patients, and evaluation of a psoriatic and arthritic questionnaire. J Rheumatol 2002;29:2577–2582.PubMedGoogle Scholar
  76. 1.
    Reece RJ, Canete JD, Parsons WJ, Emery P, Veale DJ. Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis. Arthritis Rheum 1999;42:1481–1484.PubMedCrossRefGoogle Scholar
  77. 2.
    Espinoza LR, Vasey FB, Espinoza CG, Bocanegra TS, Germain BF. Vascular changes in psoriatic synovium. A light and electron microscopic study. Arthritis Rheum 1982;25:677–684.PubMedCrossRefGoogle Scholar
  78. 3.
    Baeten D, Kruithof E, De Rycke L, et al. Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy. Arthritis Res Ther 2005;7:R359–R369.PubMedCrossRefGoogle Scholar
  79. 4.
    Smith MD, O’Donnell J, Highton J, Palmer DG, Rozenbilds M, Roberts-Thomson PJ. Immunohistochemical analysis of synovial membranes from inflammatory and non-inflammatory arthritides: scarcity of CD5 positive B cells and IL2 receptor bearing T cells. Pathology 1992;24:19–26.PubMedCrossRefGoogle Scholar
  80. 5.
    Costello PJ, Winchester RJ, Curran SA, et al. Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions appear antigen driven. J Immunol 2001;166:2878–2886.PubMedGoogle Scholar
  81. 6.
    Kruithof E, Baeten D, De Rycke L, et al. Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis [see comment]. Arthritis Res Ther 2005;7:R569–R580.PubMedCrossRefGoogle Scholar
  82. 7.
    Kane D, Jensen LE, Grehan S, Whitehead AS, Bresnihan B, Fitzgerald O. Quantitation of metalloproteinase gene expression in rheumatoid and psoriatic arthritis synovial tissue distal and proximal to the cartilage-pannus junction. J Rheumatol 1274;31:1274–1280.Google Scholar
  83. 8.
    Laloux L, Voisin MC, Allain J, et al. Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 2001;60:316–321.PubMedCrossRefGoogle Scholar
  84. 9.
    McGonagle D, Marzo-Ortega H, O’Connor P, et al. Histological assessment of the early enthesitis lesion in spondyloarthropathy. Ann Rheum Dis 2002;61:534–537.PubMedCrossRefGoogle Scholar
  85. 10.
    McGonagle D, Gibbon W, O’Connor P, Green M, Pease C, Emery P. Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondyloarthropathy. Arthritis Rheum 1998;41:694–700.PubMedCrossRefGoogle Scholar
  86. 11.
    Moll JM. Psoriatic spondylitis: clinical radiological and familial aspects. Proc Roy Soc Med 1974;67:46–50.PubMedGoogle Scholar
  87. 12.
    Gladman DD, Farewell VT, Kopciuk K, et al. HLA markers and progression in psoriatic arthritis. J Rheumatol 1998;25:730–733.PubMedGoogle Scholar
  88. 13.
    Korendowych E, Dixey J, Cox B, Jones S, McHugh N. The Influence of the HLA-DRB1 rheumatoid arthritis shared epitope on the clinical characteristics and radiological outcome of psoriatic arthritis. J Rheumatol 2003;30:96–101.PubMedGoogle Scholar
  89. 14.
    Martin MP, Nelson G, Lee JH, et al. Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol 2002;169:2818–2822.PubMedGoogle Scholar
  90. 15.
    Rahman P, Sun S, Peddle L, et al. Association between the interleukin-1 family gene cluster and psoriatic arthritis. Arthritis Rheum 2006;54:2321–2325.PubMedCrossRefGoogle Scholar
  91. 16.
    Rahman P, Siannis F, Butt C, et al. TNFalpha polymorphisms and risk of psoriatic arthritis. Ann Rheum Dis 2006;65:919–923.PubMedCrossRefGoogle Scholar
  92. 17.
    Stankler L. An experimental investigation on the site of skin damage inducing the Koebner reaction in psoriasis. Br J Dermatol 1969;81:534–535.PubMedCrossRefGoogle Scholar
  93. 18.
    Langevitz P, Buskila D, Gladman DD. Psoriatic arthritis precipitated by physical trauma. J Rheumatol 1990;17:695–697.PubMedGoogle Scholar
  94. 19.
    Rasmussen JE. The relationship between infection with group A beta hemolytic streptococci and the development of psoriasis. Pediatr Infect Dis J 2000;19:153–154.PubMedCrossRefGoogle Scholar
  95. 20.
    Wang Q, Vasey FB, Mahfood JP, et al. V2 regions of 16S ribosomal RNA used as a molecular marker for the species identification of streptococci in peripheral blood and synovial fluid from patients with psoriatic arthritis. Arthritis Rheum 1999;42:2055–2059.PubMedCrossRefGoogle Scholar
  96. 21.
    Travers JB, Hamid QA, Norris DA, et al. Epidermal HLA-DR and the enhancement of cutaneous reactivity to superantigenic toxins in psoriasis [comment]. J Clin Invest 1999;104:1181–1189.PubMedCrossRefGoogle Scholar
  97. 22.
    Zenz R, Eferl R, Kenner L, et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 2005;437:369–375.PubMedCrossRefGoogle Scholar
  98. 23.
    Jongbloed S, Lebre M, Fraser A, et al. Enumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis. Ann Rheum Dis 2005;8:R14.Google Scholar
  99. 24.
    Ritchlin C, Haas-Smith SA, Hicks D, Cappuccio J, Osterland CK, Looney RJ. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998;25:1544–1552.PubMedGoogle Scholar
  100. 25.
    Danning CL, Illei GG, Hitchon C, Greer MR, Boumpas DT, McInnes IB. Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum 2000;43:1244–1256.PubMedCrossRefGoogle Scholar
  101. 26.
    Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999;113:752–759.PubMedCrossRefGoogle Scholar
  102. 27.
    Canete JD, Pablos J, Sanmarti R, et al. Antiangiogenic effects of anti-tumor necrosis factor therapy with infliximab in psoriatic arthritis. Arthritis Rheum 2004;50:1636–1641.PubMedCrossRefGoogle Scholar
  103. 28.
    Goedkoop AY, Kraan MC, Teunissen MB, et al. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann Rheum Dis 2004;63:769–773.PubMedCrossRefGoogle Scholar
  104. 29.
    Mease PJ, Antoni CE. Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis 2005;64(Suppl 2):ii78–ii82.PubMedCrossRefGoogle Scholar
  105. 30.
    Costello P, Bresnihan B, O’Farrelly C, Fitzgerald O. Predominance of CD8+ T lymphocytes in psoriatic arthritis. J Rheumatol 1999;26:1117–1124.PubMedGoogle Scholar
  106. 31.
    Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003;111:821–831.PubMedGoogle Scholar
  107. 32.
    Gravallese EM. Bone destruction in arthritis. Ann Rheum Dis 2002;61(Suppl 2):ii84–ii86.PubMedGoogle Scholar
  108. 33.
    Braun J, Bollow M, Neure L, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995;38:499–505.PubMedCrossRefGoogle Scholar
  109. 34.
    Peng H, Wright V, Usas A, et al. Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. J Clin Invest 2002;110:751–759.PubMedGoogle Scholar
  110. 35.
    Lories RJ, Derese I, Luyten FP. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest 2005;115:1571–1579.PubMedCrossRefGoogle Scholar
  111. 36.
    Schatteman L, Mielants H, Veys EM, et al. Gut inflammation in psoriatic arthritis: a prospective ileocolonoscopic study. J Rheumatol 1995;22:680–683.PubMedGoogle Scholar
  112. 37.
    Scarpa R, Ayala F, Caporaso N, Olivieri I. Psoriasis, psoriatic arthritis, or psoriatic disease? J Rheumatology2006;33:210–212.Google Scholar
  113. 1.
    Gladman D, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64(Suppl 2):ii14–ii17.PubMedCrossRefGoogle Scholar
  114. 2.
    Mease PJ, Goffe BS. Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol 2005;52:1–19.PubMedCrossRefGoogle Scholar
  115. 3.
    Gordon KB, Ruderman EM. The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach. J Am Acad Dermatol 2006;54(Suppl 2):S85–S91.PubMedCrossRefGoogle Scholar
  116. 4.
    Gladman DD, Helliwell P, Mease PJ, Nash P, Ritchlin C, Taylor W. Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum 2004;50:24–35.PubMedCrossRefGoogle Scholar
  117. 5.
    Mease P, Antoni C, Gladman DD, Taylor W. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005;64(Suppl 2):ii49–ii54.PubMedCrossRefGoogle Scholar
  118. 6.
    Feldman SR, Krueger G. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005;64(Suppl 2):ii65–ii68.PubMedCrossRefGoogle Scholar
  119. 7.
    van der Heijde D, Sharp J, Wassenberg S, et al. Psoriatic arthritis imaging: a review of scoring methods. Ann Rheum Dis 2005;64(Suppl 2):ii61–ii64.PubMedCrossRefGoogle Scholar
  120. 8.
    Mease P, van der Heidje D. Joint damage in psoriatic arthritis: how is it assessed and can it be prevented? Int J Adv Rheumatol 2006;4:38–48.Google Scholar
  121. 9.
    Mease PJ, Menter MA. Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol 2006;54:685–704.PubMedCrossRefGoogle Scholar
  122. 10.
    Lebwohl M. A clinician’s paradigm in the treatment of psoriasis. J Am Acad Dermatol 2005;53(Suppl 1):S59–S69.PubMedCrossRefGoogle Scholar
  123. 11.
    Lebwohl M, Ting P, Koo J. Psoriasis treatment: traditional therapy. Ann Rheum Dis 2005;64(Suppl 64):ii83–ii86.PubMedCrossRefGoogle Scholar
  124. 12.
    Koo JY. New developments in topical sequential therapy for psoriasis. Skin Therapy Lett 2005;10:1–4.PubMedGoogle Scholar
  125. 13.
    Fairhurst DA, Ashcroft DM, Griffiths CE. Optimal management of severe plaque form of psoriasis. Am J Clin Dermatol 2005;6:283–294.PubMedCrossRefGoogle Scholar
  126. 14.
    Naldi L, Griffiths CE. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 2005;152:597–615.PubMedCrossRefGoogle Scholar
  127. 15.
    Norris DA. Mechanisms of action of topical therapies and the rationale for combination therapy. J Am Acad Dermatol 2005;53(Suppl 1):S17–S25.PubMedCrossRefGoogle Scholar
  128. 16.
    Krueger G, Ellis CN. Psoriasis–recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol 2005;53(Suppl 1):S94–S100.PubMedCrossRefGoogle Scholar
  129. 17.
    Feldman SR, Koo JY, Menter A, Bagel J. Decision points for the initiation of systemic treatment for psoriasis. J Am Acad Dermatol 2005;53:101–107.PubMedCrossRefGoogle Scholar
  130. 18.
    Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014–2022.PubMedCrossRefGoogle Scholar
  131. 19.
    Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1367–1374.PubMedCrossRefGoogle Scholar
  132. 20.
    Langley R, Leonardi CL, Hoffman R. Long-term safety and efficacy of Adalimumab in the treatment of moderate to severe chronic plaque psoriasis. Paper presented at: American Academy of Dermatology Annual Meeting; February 18–20, 2005; New Orleans, LA.Google Scholar
  133. 21.
    Krueger GG, Papp KA, Sough DB, et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002;47:821–833.PubMedCrossRefGoogle Scholar
  134. 22.
    Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;349:2004–2013.PubMedCrossRefGoogle Scholar
  135. 23.
    Fiorentino D, Mease P. The skin in psoriatic arthritis. Int J Adv Rheumatol 2005;3:110–117.Google Scholar
  136. 24.
    Winterfield L, Menter A, Gordon KB, Gottlieb A. Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis 2005;64(Suppl 64):ii87–ii90.PubMedCrossRefGoogle Scholar
  137. 25.
    Krueger G, Ellis CN. Psoriasis–recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol 2005;53(Suppl 1):S94–S100.PubMedCrossRefGoogle Scholar
  138. 26.
    Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002;46:1–23; quiz 6.PubMedCrossRefGoogle Scholar
  139. 27.
    Nash P, Clegg DO. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 2005;64(Suppl 2):ii74–ii77.PubMedCrossRefGoogle Scholar
  140. 28.
    Braun J, Baraliakos X, Godolias G, Bohm H. Therapy of ankylosing spondylitis–a review. Part I: Conventional medical treatment and surgical therapy. Scand J Rheumatol 2005;34:97–108.PubMedCrossRefGoogle Scholar
  141. 29.
    Willkens RF, Williams HJ, Ward JR, et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984;27:376–381.PubMedCrossRefGoogle Scholar
  142. 30.
    van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006;54:1063–1074.PubMedCrossRefGoogle Scholar
  143. 31.
    Abu-Shakra M, Gladman DD, Thorne JC, Long JA, Gough J, Farewell VT. Long-term methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol 1995;22:241–245.PubMedGoogle Scholar
  144. 32.
    Whiting-O’Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991;90:711–716.PubMedGoogle Scholar
  145. 33.
    Roenigk HH Jr, Auerbach R, Maibach H, Weinstein G, Lebwohl M. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998;38:478–485.PubMedCrossRefGoogle Scholar
  146. 34.
    Kremer JM, Alarcon GS, Lightfoot RW Jr., et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994;37:316–328.PubMedCrossRefGoogle Scholar
  147. 35.
    Thomas JA, Aithal GP. Monitoring liver function during methotrexate therapy for psoriasis: are routine biopsies really necessary? Am J Clin Dermatol 2005;6:357–363.PubMedCrossRefGoogle Scholar
  148. 36.
    Braun J, Baraliakos X, Brandt J, Sieper J. Therapy of ankylosing spondylitis. Part II: biological therapies in the spondyloarthritides. Scand J Rheumatol 2005;34:178–190.PubMedCrossRefGoogle Scholar
  149. 37.
    Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2013–2020.PubMedCrossRefGoogle Scholar
  150. 38.
    Fraser AD, van Kuijk AW, Westhovens R, et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus cyclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 2005;64:859–864.PubMedCrossRefGoogle Scholar
  151. 39.
    Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis. Arthritis Rheum 2004;50:1939–1950.PubMedCrossRefGoogle Scholar
  152. 40.
    Enbrel® (etanercept) prescribing information. Thousand Oaks, CA: Immunex Corporation; 2003.Google Scholar
  153. 41.
    Remicade (infliximab) prescribing information. Malvern, PA: Centocor Inc; 2003.Google Scholar
  154. 42.
    HumiraTM (adalimumab) prescribing information. North Chicago, IL: Abbott Laboratories; 2003.Google Scholar
  155. 43.
    Mease P, Kivitz A, Burch F, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264–2272.PubMedCrossRefGoogle Scholar
  156. 44.
    Mease P, Ganguly L, Wanke E, Yu E, Singh A. How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the outcome measures in rheumatoid arthritis clinical trials (OMERACT) group guidelines. Ann Rheum Dis 2004;63(Suppl 1):391.Google Scholar
  157. 45.
    Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006;33:712–721.PubMedGoogle Scholar
  158. 46.
    Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150–1157.PubMedCrossRefGoogle Scholar
  159. 47.
    van der Heijde D, Kavanaugh A, Beutler A, et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic damage in patients with arthritis: results from IMPACT 2 trial. Ann Rheum Dis 2005;64(Suppl 3):109.Google Scholar
  160. 48.
    Mease P, Gladman D, Ritchlin C. Adalimumab in the treatment of patients with moderately to severely active psoriatic arthritis: results of ADEPT. Arthritis Rheum 2005;58:3279–3289.CrossRefGoogle Scholar
  161. 49.
    Zochling J, van der Heijde D, Dougados M, Braun J. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the asas/eular management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006;65:423–432.PubMedCrossRefGoogle Scholar
  162. 50.
    Bansback N, Barkham N, Ara R, et al. The economic implications of TNF-inhibitors in the treatment of psoriatic arthritis. Arthritis Rheum 2004;50(Suppl 9):S509.Google Scholar
  163. 51.
    Guh D, Bansback N, Nosyk B, Melilli L, Anis A. Improvement in health utility in patients with psoriatic arthritis treated with adalimumab (Humira). Ann Rheum Dis 2005;64(Suppl 3):401.Google Scholar
  164. 52.
    Marra CA. Valuing health states and preferences of patients. Ann Rheum Dis 2005;64(Suppl 3):36.Google Scholar
  165. 53.
    Kraan MC, van Kuijk AW, Dinant HJ, et al. Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum 2002;46:2776–2784.PubMedCrossRefGoogle Scholar
  166. 54.
    Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003;139:719–727.PubMedCrossRefGoogle Scholar
  167. 55.
    Mease PJ, Gladman DD, Keystone EC. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2006;54:1638–1645.PubMedCrossRefGoogle Scholar
  168. 56.
    Papp KA, Caro I, Leung HM, Garovoy M, Mease PJ. Efalizumab for the treatment of psoriatic arthritis. J Cutan Med Surg 2007;11:57–66.PubMedGoogle Scholar
  169. 57.
    Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349:1907–1915.PubMedCrossRefGoogle Scholar
  170. 58.
    Abrams JR, Lebwohl M, Guzzo C. CTLA4Ig-mediated blockade of T cell co-stimulation in patients with psoriasis vulgaris. J Clin Invest 1999;103:1243–1252.PubMedCrossRefGoogle Scholar
  171. 59.
    McInnes IB, Gracie JA. Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004;4:392–397.PubMedCrossRefGoogle Scholar
  172. 60.
    Gibbs A, Gogarty M, Veale D, Bresnihan B, Fitzgerald O. Efficacy of anakinara (Kineret) in psoriatic arthritis, a clinical and immunohistological study. Ann Rheum Dis 2006;65(Suppl 2):216.CrossRefGoogle Scholar
  173. 61.
    Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treat-ment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50:1761–1769.PubMedCrossRefGoogle Scholar
  174. 62.
    Krueger C, Langley R, Leonardi C, Lebwohl M. Results of a phase II study of CNTO 1275 in the treatment of psoriasis. J Am Acad Dermatol 2006;54:AB10.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Dafna D. Gladman
    • 1
    • 2
    • 3
  1. 1.Department of Medicine/RheumatologyUniversity of TorontoTorontoCanada
  2. 2.Toronto Western Research InstituteTorontoCanada
  3. 3.Psoriatic Arthritis Program, University Health NetworkTorontoCanada

Personalised recommendations